WO2000038669A3 - Methode de prevention et de traitement de la degeneration des neurones - Google Patents
Methode de prevention et de traitement de la degeneration des neurones Download PDFInfo
- Publication number
- WO2000038669A3 WO2000038669A3 PCT/US1999/031070 US9931070W WO0038669A3 WO 2000038669 A3 WO2000038669 A3 WO 2000038669A3 US 9931070 W US9931070 W US 9931070W WO 0038669 A3 WO0038669 A3 WO 0038669A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- degeneration
- neurons
- treating
- preventing
- naloxone
- Prior art date
Links
- 230000007850 degeneration Effects 0.000 title abstract 3
- 210000002569 neuron Anatomy 0.000 title abstract 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title 1
- 229960004127 naloxone Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000005064 dopaminergic neuron Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 210000003523 substantia nigra Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Laminated Bodies (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une technique de provocation de symptômes de type Parkinson chez des animaux par injection de lipopolysaccharides dans le locus niger. L'invention concerne en outre une méthode de prévention et de traitement de la dégénération de neurones dans une région du cerveau, notamment la dégénération de neurones dopaminergiques dans le locus niger, associée à la maladie de Parkinson.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23935/00A AU2393500A (en) | 1998-12-29 | 1999-12-29 | Method for preventing and treating the degeneration of neurons |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11421498P | 1998-12-29 | 1998-12-29 | |
US60/114,214 | 1998-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000038669A2 WO2000038669A2 (fr) | 2000-07-06 |
WO2000038669A3 true WO2000038669A3 (fr) | 2001-10-11 |
Family
ID=22353984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/031070 WO2000038669A2 (fr) | 1998-12-29 | 1999-12-29 | Methode de prevention et de traitement de la degeneration des neurones |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2393500A (fr) |
CO (1) | CO5111024A1 (fr) |
WO (1) | WO2000038669A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7309497B2 (en) | 2000-08-24 | 2007-12-18 | Schwarz Pharma Ag | Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
US7151961B1 (en) | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
DE10361259A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
WO2005112931A2 (fr) * | 2004-05-12 | 2005-12-01 | The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services | Procédés liés au traitement d'affections neurodégénératives et inflammatoires |
-
1999
- 1999-12-27 CO CO99080706A patent/CO5111024A1/es unknown
- 1999-12-29 AU AU23935/00A patent/AU2393500A/en not_active Abandoned
- 1999-12-29 WO PCT/US1999/031070 patent/WO2000038669A2/fr active Application Filing
Non-Patent Citations (23)
Title |
---|
A. CASTAÑO ET AL.: "Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System", JOURNAL OF NEUROCHEMISTRY, vol. 70, no. 4, April 1998 (1998-04-01), pages 1584 - 1592, XP000982792 * |
A.M. SZCZEPANIK ET AL.: "EFFECTS OF CHRONIC INTRAHIPPOCAMPAL INFUSION OF LIPOPOLYSACCHARIDE IN THE RAT", NEUROSCIENCE, vol. 70, no. 1, 1996, pages 57 - 65, XP000982798 * |
A.M.S. MAYER: "THERAPEUTIC IMPLICATIONS OF MICROGLIA ACTIVATION BY LIPOPOLYSACCHARIDE AND REACTIVE OXYGEN SPECIES GENERATION IN SEPTIC SHOCK AND CENTRAL NERVOUS SYSTEM PATHOLOGIES: A REVIEW", MEDICINA (SHOCK 1998: OXYGEN, NITRIC OXIDE AND THERAPEUTIC PERSPECTIVES, INTERNATIONAL SYMPOSIUM, ACADEMIA NACIONAL DE MEDICINA, BUENES AIRES, 30 APRIL 1998), vol. 58, no. 4, 1998, pages 377 - 385, XP000982794 * |
A.P.LIEBERMAN ET AL.: "Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus", PROC. NATL. ACAD. SCI USA, vol. 86, August 1989 (1989-08-01), pages 6348 - 6352, XP000982744 * |
AGNOLI, A. ET AL: "Are the enkephalins involved in Parkinson's disease? Clinical and neuroendocrine responses to naloxone administration", ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY, vol. 22, 1980, pages 511 - 521, XP000900514 * |
C.N. MONTERO-MENEI ET AL.: "Early events of the inflammatory reaction induced in rat brain by lipopolysaccharide intracerebral injection: relative contribution of peripheral monocytes and activated microglia", BRAIN RESEARCH, vol. 724, no. 1, 10 June 1996 (1996-06-10), pages 55 - 66, XP000982796 * |
C.N. MONTERO-MENEI ET AL.: "Lipopolysaccharide intracerebral administration induces minimal inflammatory reaction in rat brain", BRAIN RESEARCH, vol. 653, no. 1-2, 8 August 1994 (1994-08-08), pages 101 - 111, XP000982797 * |
CAREY, R.J.: "Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue", LIFE SCIENCES, vol. 48, no. 13, 1991, pages 1303 - 1308, XP000934331 * |
DIAMOND, B.I. ET AL: "Enkephalins and nigrostriatal function", NEUROLOGY, vol. 28, no. 11, 1978, pages 1085 - 1088, XP000934332 * |
F. CASAMENTI ET AL.: "MORPHOLOGICAL, BIOCHEMICAL AND BEHAVIOURAL CHANGES INDUCED BY NEUROTOXIC AND INFLAMMATORY INSULTS TO THE NUCLEUS BASALIS", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, vol. 16, no. 7-8, November 1998 (1998-11-01) - December 1998 (1998-12-01), pages 705 - 714, XP000982800 * |
FEIGENBAUM, J. ETAL: "Possible DA agonist properties of naloxone", INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol. 17, no. 3, 1982, pages 139 - 144, XP000934340 * |
G.Y. BING ET AL.: "MICROGLIA MEDIATED DOPAMINERGIC CELL DEATH IN THE SUBSTANTIA NIGRA: A NEW ANIMAL MODEL FOR PARKINSON'S DISEASE", SOCIETY FOR NEUROSCIENCE ABSTRACTS (28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2; LOS ANGELES, CALIFORNIA, USA, NOVEMBER 7-12, 1998), vol. 24, no. 1-2, 1998, pages 1466, XP000982790 * |
HAAG, T. ET AL: "Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 90, 1993, pages 6315 - 6319, XP000929833 * |
J. LUTHMAN ET AL.: "Effects of the 3-hydroxyanthranilic analogue NCR-631 on anoxia-, IL-1beta- and LPS-induced hippocampal pyramidal cell loss in vitro", AMINO ACIDS, vol. 14, no. 1-3, 1998, pages 263 - 269, XP000982829 * |
LIU, B. ET AL: "Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 293, no. 2, May 2000 (2000-05-01), pages 607 - 617, XP000934290 * |
LU, X. ET AL: "Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats", NEUROSCIENCE, vol. 97, no. 2, 28 April 2000 (2000-04-28), pages 285 - 291, XP000934248 * |
M.M. IRAVANI ET AL.: "DOPAMINE CELL LOSS AND EXPRESSION OF INDUCIBLE NITRIC OXIDE SYNTHASE IMMUNOREACTIVITY FOLLOWING INTRANIGRAL INJECTION OF LIPOPOLYSACCHARIDE", BRITISH JOURNAL OF PHARMACOLOGY, vol. 125, no. PROC. SUPPL., 8 September 1998 (1998-09-08) - 11 September 1998 (1998-09-11), pages 44P, XP000982795 * |
QUOCK, R.M. ET AL: "Potentiation by naloxone of the anti-oxotremorine effect of L-dopa", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 95, no. 3-4, 1983, pages 193 - 198, XP000934329 * |
S. MUN-BRYCE ET AL.: "Gelatinase B modulates selective opening of the blood-brain barrier during inflammation", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 274, no. 5 Part 2, May 1998 (1998-05-01), pages R1203 - R1211, XP000982793 * |
S.C. LEE ET AL.: "Cytokine Production by Human Fetak Microglia and Astrocytes", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 7, 1 April 1993 (1993-04-01), pages 2659 - 2667, XP000982745 * |
S.F. SHARIF ET AL.: "Human astrocyte production of tumour necrosis factor.alpha, interleukin-1beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin", NEUROL.RES., vol. 15, no. 2, April 1993 (1993-04-01), pages 109 - 112, XP000979390 * |
SANDYK, R. ET AL: "Naloxone treatment of L-dopa induced dyskinesias in Parkinson's disease", THE AMERICAN JOURNAL OF PSYCHIATRY, vol. 143, no. 1, 1986, pages 118, XP000934289 * |
TRABUCCHI, M. ET AL: "Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy", ARCHIVES OF NEUROLOGY, vol. 39, no. 2, 1982, pages 120 - 121, XP000934326 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7309497B2 (en) | 2000-08-24 | 2007-12-18 | Schwarz Pharma Ag | Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients |
Also Published As
Publication number | Publication date |
---|---|
CO5111024A1 (es) | 2001-12-26 |
WO2000038669A2 (fr) | 2000-07-06 |
AU2393500A (en) | 2000-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997034586A3 (fr) | Dispositif et methode de traitement de maladies ophtalmiques | |
EP1466606A3 (fr) | Utilisation de l'inosine dans la fabrication d'un medicament pour stimuler l'excroissance des neurons du système nerveux central | |
ES2168006T3 (es) | Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. | |
MXPA02003724A (es) | Uso de un inhibidor selectivo de la recaptacion de noradrenalina combinado con felilalanina o tirosina y composicion. | |
EP1140104A4 (fr) | Methode permettant d'augmenter in vivo les niveaux de cytidine et traitement des maladies humaines dependant de la cytidine | |
WO1999045949A3 (fr) | Utilisation de la follistatine pour moduler gdf-8 et bmp-11 | |
WO2002051433A3 (fr) | Nouvelle utilisation de l'artemine, membre de la famille de ligands du facteur de croissance gdnf | |
AU1833699A (en) | Device and method for treating parkinson's disease | |
WO2000050568A3 (fr) | Transplantation de cellules hematopoietiques | |
AU2003296341A8 (en) | System and method for treating Parkinson's Disease and other movement disorders | |
WO2001058476A3 (fr) | Procedes et compositions pour le traitement de la maladie d'alzheimer par le renforcement de l'activite de la plasmine ou de l'activite du type de la plasmine | |
WO2002049626A3 (fr) | Nouveau traitement | |
WO2000038669A3 (fr) | Methode de prevention et de traitement de la degeneration des neurones | |
WO2002056745A3 (fr) | Methode de traitement de la maladie de parkinson | |
WO2001007026A3 (fr) | Methode de traitement amelioree du diabete de type ii et de l'obesite | |
WO1999048489A3 (fr) | Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose | |
AUPP674898A0 (en) | A method of treatment | |
CA2347863A1 (fr) | Traitement des affections de la retine | |
EP1106609A3 (fr) | Dérivé d'aminoalcool et médicament comprenant ledit dérivé | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
WO1999059563A3 (fr) | Cabergoline et pramipexole: nouvelles utilisations et combinaisons | |
CA2246560A1 (fr) | Methodes d'administration d'un antagoniste du recepteur ampa pour traiter les dyskinesies associees a la therapie par un agoniste de la dopamine | |
HK1042238A1 (en) | Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group | |
AU6258798A (en) | Facilitation of repair of neural injury with cm101/gbs toxin | |
WO2000021978A3 (fr) | Laminine 5, 13 et 14 ainsi que leurs applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |